Angiex Inc.

Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality and deliver safe and effective cancer therapies to all. 

Angiex founders discovered the special biology of the intracellular transporter TM4SF1.

TM4SF1 is normally specific to endothelial cells (the cells lining the walls of blood vessels) where it enables new blood vessels to grow. But TM4SF1 is commonly turned on by malignant cancer cells because it enables them to invade and metastasize.

TM4SF1 is widely and highly expressed in the tumor cells of most solid cancers and in the endothelial cells of angiogenic tumor blood vessels. Drugs directed to TM4SF1 can therefore attack both Angiogenesis and Invasion and Metastasis. Moreover, because the endothelium controls immune cell trafficking into tumors, TM4SF1-directed drugs can potentially overcome cancer’s Suppression of Immune Defense.